Clinical Studies

Clinical research is very important because it is one of the best ways to improve patient care. Currently, hundreds of studies are taking place throughout Lurie Children's, including at the research institute, that involve many of our doctors, nurses, clinical research professionals, scientists and technicians.

Search below for a clinical study, or to see a more comprehensive listing of the clinical studies taking place at Lurie Children's, please use our link to the ClinicalTrials.gov website.

You can learn more about the clinical research process on our guide to clinical research for parents and children.

Filter by:

Studies

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

ClinicalTrials.gov ID: NCT01767194

This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or monoclonal antibody Ch14.18 work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to...

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

ClinicalTrials.gov ID: NCT00392327

This randomized phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Drugs used in chemotherapy, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways...

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 (Prism301)

ClinicalTrials.gov ID: NCT01819727

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in patients equal or greater than 18 years old with hyperphenylalaninemia due to PKU. Study BMN 165-301 is a Phase 3, open-label, randomized study designed to further characterize the safety of BMN 165...

An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

ClinicalTrials.gov ID: NCT01886378

UX007-CL201 is an open-label Phase 2 study to assess the safety and clinical effects of UX007 in subjects with LC-FAOD. Following a 4 week run in period on current therapy, subjects will cross over to daily UX007 treatment for an initial 24 week treatment period, followed by an additional 54 week extension period. Approximately 30 subjects at...